Compare Direxion Daily CSI China Internet Bull 2X Shares (CWEB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily CSI China Internet Bull 2X Shares vs TG Therapeutics Inc — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $23.4, while TG Therapeutics Inc trades at $50.43 (market cap $7.64B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| CWEB | TGTX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $60.13 | $59.06 |
52-Week Low | $17.70 | $26.94 |
Market Cap | — | $7.64B |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CWEB trades at $23.74, down 9.94% over 24 hours, with technical indicators showing mixed signals—moving averages are bearish while oscillators are neutral. The stock exhibits a bullish overall signal, supported by strong ADX readings indicating a trending market. Recent news highlights potential renewed interest in China growth stocks following a related IPO, which could benefit CWEB.
The outlook for CWEB hinges on positive sentiment around China equities, but risks include market volatility and geopolitical factors. Key support is at $24, with resistance at $25. Investors should monitor earnings reports for fundamental validation, as current financial ratios are unavailable, limiting valuation clarity.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
